top of page

A NOVEL APPROACH TO

AIRWAY DISEASES

Find out more about our unique therapeutic strategy

Our non-antibiotic macrolide platform addresses epithelial dysfunction and other key drivers of inflammation in chronic respiratory diseases.

Home: Products

Tackling one of the world's most prevalent diseases

Chronic obstructive pulmonary disease (COPD) afflicts more than a quarter of a billion people globally, leading to more than 3 million deaths every year.

The unmet need for disease-modifying therapies for COPD

There are no clinical trials showing that any existing medications for COPD modify the long-term decline in lung function that characterizes COPD.

A new paradigm of epithelial barrier insufficiency

Find out more about our unique approach targeting epithelial barrier insufficiency as a key driver of inflammation in chronic respiratory diseases.

CONTACT US

Contact

CONTACT DETAILS

Bjargargata 1

102 Reykjavík

Iceland

info@epiendo.com

Main Office    [+354] 454 0095

SEND US A MESSAGE

Thanks for submitting!

bottom of page